uBiome
uBiome, a biotech accelerated by Y Combinator in the S14 batch, with a $4.5M round from angels and Andreessen Horowitz, took microbiome sequencing to consumers: the user swabs at home, mails the sample in and reads the results in a web app, the press's "23andMe of the gut".
The design covered everything the customer touched between kit and results on Explorer, the consumer line: kit registration, guided sampling and dashboards that show microbiome composition over time, what changed between samples and how the user compares with lifestyle cohorts.
Since nobody can picture their own microbiome, the screens carry people through an unfamiliar process and translate bacterial data for people with no lab background, never crossing into diagnosis. What the company did later is at the end of this page.
Afterwards
The design work ended years before the company did. In April 2019 the FBI searched uBiome's San Francisco offices over its insurance billing; CNBC reported double-billing and seized computers. Clinical operations were suspended, and the company filed for Chapter 11 in September 2019, then Chapter 7. In 2021 the SEC charged the founders over roughly $60M in Series C fraud and the DOJ alleged around $76M in investor fraud. The founders were later listed as FBI fugitives.
- Client
- uBiome
- Role
- UI/UX Designer
- Year
- 2014 – 2015
- Location
- San Francisco, USA
- Category
- Biotech / UI/UX
- Services
- UI/UX Design
- Product Design
- Information Architecture
- Press
Challenge
Make at-home microbiome testing readable to anyone.
Solution
Registration, guided sampling and plain-language results, no diagnosis.
Results
- Full consumer product of the YC S14 line, from kit to results
- Sequencing data turned into dashboards anyone can read
- Citizen-science flow shipped: register, sample, survey, results